Advertisement

Management of Severe Skin Eruptions

  • Katherine Menson
  • Garth W. GarrisonEmail author
Chapter
  • 6 Downloads

Abstract

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) represent a continuum of severe mucocutaneous eruptions associated with significant morbidity. The condition is characterized by diffuse erythematous purpuric macules or flat targetoid lesions that evolve into vesicles and bullae followed by skin sloughing. The skin changes are nearly always associated with mucosal involvement. SJS/TEN is typically induced by medication use, but can be triggered by bacterial or viral infections. Management involves removal of the offending agent and supportive care. The evidence supporting corticosteroids and IVIG is lacking, although evidence of new therapies is emerging. In this chapter, the diagnosis and management of SJS/TEN will be discussed. The conflicting data on systemic therapy is addressed.

Keywords

Stevens-Johnson syndrome SJS Toxic epidermal necrolysis TEN Skin eruption Blister Drug reaction Drug rash 

References

  1. 1.
    Habif TP. Clinical dermatology a color guide to diagnosis and therapy. 6th edition. ed:1 online resource color illustrations. 2015Google Scholar
  2. 2.
    Braun-Falco O. Dermatology . 2nd, completely rev. edition. Berlin; New York: Springer; 2000.Google Scholar
  3. 3.
    Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149–53.CrossRefGoogle Scholar
  4. 4.
    Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal Necrolysis in United States adults. J Invest Dermatol. 2016;136(7):1387–97.CrossRefGoogle Scholar
  5. 5.
    Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T. Current perspectives on Stevens-Johnson syndrome and toxic epidermal Necrolysis. Clin Rev Allergy Immunol. 2018;54(1):147–76.CrossRefGoogle Scholar
  6. 6.
    Yip LW, Thong BY, Lim J, Tan AW, Wong HB, Handa S, et al. Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series. Allergy. 2007;62(5):527–31.CrossRefGoogle Scholar
  7. 7.
    Gregory DG. New grading system and treatment guidelines for the acute ocular manifestations of Stevens-Johnson syndrome. Ophthalmology. 2016;123(8):1653–8.CrossRefGoogle Scholar
  8. 8.
    Sassolas B, Haddad C, Mockenhaupt M, Dunant A, Liss Y, Bork K, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010;88(1):60–8.CrossRefGoogle Scholar
  9. 9.
    de Prost N, Mekontso-Dessap A, Valeyrie-Allanore L, Van Nhieu JT, Duong TA, Chosidow O, et al. Acute respiratory failure in patients with toxic epidermal necrolysis: clinical features and factors associated with mechanical ventilation. Crit Care Med. 2014;42(1):118–28.CrossRefGoogle Scholar
  10. 10.
    Seccombe E, Ardern-Jones M, Walker W, Austin S, Taibjee S, Williams S, et al. Bronchiolitis Obliterans as long-term sequela of non-drug related Stevens-Johnson syndrome and toxic epidermal Necrolysis in children. Clin Exp Dermatol. 2019;Google Scholar
  11. 11.
    Morelli MS, O'Brien FX. Stevens-Johnson syndrome and cholestatic hepatitis. Dig Dis Sci. 2001;46(11):2385–8.CrossRefGoogle Scholar
  12. 12.
    Carter FM, Mitchell CK. Toxic epidermal necrolysis--an unusual cause of colonic perforation. Report of a case. Dis Colon Rectum. 1993;36(8):773–7.CrossRefGoogle Scholar
  13. 13.
    Jha AK, Suchismita A, Jha RK, Raj VK. Spectrum of gastrointestinal involvement in Stevens - Johnson syndrome. World J Gastrointest Endosc. 2019;11(2):115–23.CrossRefGoogle Scholar
  14. 14.
    Ko TM, Chung WH, Wei CY, Shih HY, Chen JK, Lin CH, et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol. 2011;128(6):1266–76 e11.CrossRefGoogle Scholar
  15. 15.
    Fang H, Xu X, Kaur K, Dedek M, Zhu GD, Riley BJ, et al. A screening test for HLA-B( ∗)15:02 in a large United States patient cohort identifies broader risk of carbamazepine-induced adverse events. Front Pharmacol. 2019;10:149.CrossRefGoogle Scholar
  16. 16.
    Orime M. Immunohistopathological findings of severe cutaneous adverse drug reactions. J Immunol Res. 2017;2017:6928363.CrossRefGoogle Scholar
  17. 17.
    Palmieri TL, Greenhalgh DG, Saffle JR, Spence RJ, Peck MD, Jeng JC, et al. A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil. 2002;23(2):87–96.CrossRefGoogle Scholar
  18. 18.
    Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol. 2013;69(2):187. e1–16; quiz 203–4CrossRefGoogle Scholar
  19. 19.
    Xia W, Mao C, Luo X, Xu J, Chen X, Lin C. A 13-year retrospective study evaluating the efficacy of using air-fluidised beds for toxic epidermal necrolysis patients. Australas J Dermatol. 2016;57(3):205–9.CrossRefGoogle Scholar
  20. 20.
    Dorafshar AH, Dickie SR, Cohn AB, Aycock JK, O'Connor A, Tung A, et al. Antishear therapy for toxic epidermal necrolysis: an alternative treatment approach. Plast Reconstr Surg. 2008;122(1):154–60.CrossRefGoogle Scholar
  21. 21.
    Mahar PD, Wasiak J, Cleland H, Paul E, Gin D, Watters DA, et al. Secondary bacterial infection and empirical antibiotic use in toxic epidermal necrolysis patients. J Burn Care Res. 2014;35(6):518–24.CrossRefGoogle Scholar
  22. 22.
    Fine JD. Management of acquired bullous skin diseases. N Engl J Med. 1995;333(22):1475–84.CrossRefGoogle Scholar
  23. 23.
    Hazin R, Ibrahimi OA, Hazin MI, Kimyai-Asadi A. Stevens-Johnson syndrome: pathogenesis, diagnosis, and management. Ann Med. 2008;40(2):129–38.CrossRefGoogle Scholar
  24. 24.
    Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study. J Am Acad Dermatol. 2008;58(1):33–40.CrossRefGoogle Scholar
  25. 25.
    Huang YC, Li YC, Chen TJ. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis. Br J Dermatol. 2012;167(2):424–32.CrossRefGoogle Scholar
  26. 26.
    Chan L, Cook DK. A 10-year retrospective cohort study of the management of toxic epidermal necrolysis and Stevens-Johnson syndrome in a New South Wales state referral hospital from 2006 to 2016. Int J Dermatol. 2019;Google Scholar
  27. 27.
    Valeyrie-Allanore L, Wolkenstein P, Brochard L, Ortonne N, Maitre B, Revuz J, et al. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2010;163(4):847–53.CrossRefGoogle Scholar
  28. 28.
    Singh GK, Chatterjee M, Verma R. Cyclosporine in Stevens Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with systemic corticosteroid. Indian J Dermatol Venereol Leprol. 2013;79(5):686–92.CrossRefGoogle Scholar
  29. 29.
    Kirchhof MG, Miliszewski MA, Sikora S, Papp A, Dutz JP. Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. J Am Acad Dermatol. 2014;71(5):941–7.CrossRefGoogle Scholar
  30. 30.
    Ng QX, De Deyn M, Venkatanarayanan N, Ho CYX, Yeo WS. A meta-analysis of cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis. J Inflamm Res. 2018;11:135–42.CrossRefGoogle Scholar
  31. 31.
    Wang CW, Yang LY, Chen CB, Ho HC, Hung SI, Yang CH, et al. Randomized, controlled trial of TNF-alpha antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Invest. 2018;128(3):985–96.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Pulmonary & Critical Care MedicineUniversity of Vermont Medical CenterBurlingtonUSA

Personalised recommendations